Vergelijking

Amycretin vs. Eloralintide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Amycretin	Eloralintide
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Amycretin

Volledige vermelding →

Eloralintide

Volledige vermelding →

Frequently asked questions

What is the difference between Amycretin and Eloralintide?: Amycretin is classified as "Metabool", while Eloralintide is classified as "Metabool". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Eloralintide?: The highest available evidence level is "Humane RCT" for Amycretin and "Humane RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Eloralintide in Germany and the United States?: Duitsland: Amycretin — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. Verenigde Staten: Amycretin — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Eloralintide

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Amycretin and Eloralintide?

Amycretin is classified as "Metabool", while Eloralintide is classified as "Metabool". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Eloralintide?

The highest available evidence level is "Humane RCT" for Amycretin and "Humane RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Eloralintide in Germany and the United States?

Duitsland: Amycretin — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. Verenigde Staten: Amycretin — Niet goedgekeurd, Eloralintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.